1. Home
  2. SNPS vs BMY Comparison

SNPS vs BMY Comparison

Compare SNPS & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNPS
  • BMY
  • Stock Information
  • Founded
  • SNPS 1986
  • BMY 1887
  • Country
  • SNPS United States
  • BMY United States
  • Employees
  • SNPS N/A
  • BMY N/A
  • Industry
  • SNPS EDP Services
  • BMY Biotechnology: Pharmaceutical Preparations
  • Sector
  • SNPS Technology
  • BMY Health Care
  • Exchange
  • SNPS Nasdaq
  • BMY Nasdaq
  • Market Cap
  • SNPS 112.2B
  • BMY 94.0B
  • IPO Year
  • SNPS 1992
  • BMY N/A
  • Fundamental
  • Price
  • SNPS $425.97
  • BMY $46.33
  • Analyst Decision
  • SNPS Buy
  • BMY Hold
  • Analyst Count
  • SNPS 15
  • BMY 15
  • Target Price
  • SNPS $578.33
  • BMY $57.64
  • AVG Volume (30 Days)
  • SNPS 3.4M
  • BMY 9.4M
  • Earning Date
  • SNPS 09-09-2025
  • BMY 10-30-2025
  • Dividend Yield
  • SNPS N/A
  • BMY 5.35%
  • EPS Growth
  • SNPS 31.64
  • BMY N/A
  • EPS
  • SNPS 12.67
  • BMY 2.49
  • Revenue
  • SNPS $6,435,304,000.00
  • BMY $47,704,000,000.00
  • Revenue This Year
  • SNPS $14.94
  • BMY N/A
  • Revenue Next Year
  • SNPS $18.70
  • BMY N/A
  • P/E Ratio
  • SNPS $33.61
  • BMY $18.63
  • Revenue Growth
  • SNPS 8.00
  • BMY 2.57
  • 52 Week Low
  • SNPS $365.74
  • BMY $42.96
  • 52 Week High
  • SNPS $651.73
  • BMY $63.33
  • Technical
  • Relative Strength Index (RSI)
  • SNPS 28.37
  • BMY 44.24
  • Support Level
  • SNPS $416.79
  • BMY $46.00
  • Resistance Level
  • SNPS $444.19
  • BMY $48.19
  • Average True Range (ATR)
  • SNPS 17.98
  • BMY 0.92
  • MACD
  • SNPS -21.48
  • BMY -0.12
  • Stochastic Oscillator
  • SNPS 19.21
  • BMY 18.05

About SNPS Synopsys Inc.

Synopsys is a provider of electronic design automation software and intellectual property products. EDA software automates and aids in the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Synopsys' comprehensive portfolio is benefiting from a convergence of semiconductor companies moving up the stack of technologies toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.

About BMY Bristol-Myers Squibb Company

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Share on Social Networks: